Search - tctmd.com

Displaying 721 - 740 of 1865

Sort: Relevancy | Date

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

News Conference News EHRA 2019

High-Dose Nifedipine Tied to Higher Cardiac Arrest Risk

Todd Neale

March 18, 2019

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Caitlin E. Cox

March 17, 2019

Presentation OPCI 2019

Optimal Duration of Antiplatelet Therapy – Does IV Imaging Make A Difference?

Presenter: Roxana Mehran

March 09, 2019

Presentation OPCI 2019

When treating (severely) calcified CAD, rotational or orbital atherectomy is mandatory

Presenter: Emmanouil S. Brilakis

March 09, 2019

Presentation OPCI 2019

Show Me the Data: Evidence That Physiologic Lesion Assessment Improves Patient Outcomes

Presenter: Habib Samady

March 09, 2019

Presentation OPCI 2019

High Definition IVUS as a tool to optimize PCI

Presenter: Akiko Maehara

March 09, 2019

Presentation OPCI 2019

Basics of Coronary Physiology: FFR-Guided PCI in Stable CAD

Presenter: William F. Fearon

March 09, 2019

News Conference News CRT 2019

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

Yael L. Maxwell

March 03, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

Majority of SCAD Lesions Heal With Conservative Treatment

Michael O'Riordan

February 27, 2019

News Daily News

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

L.A. McKeown

February 26, 2019

News Daily News

CT Angiography Bests Functional Testing in Diabetic Patients With Chest Pain: PROMISE

Michael O'Riordan

February 25, 2019

News Daily News

Quality of CAD Care Varies by Type of Medicare Coverage

Todd Neale

February 20, 2019

Presentation JIM 2019

Consider Low Dose RIVAROXABAN + SAPT

Presenter: Roxana Mehran

February 15, 2019

Presentation JIM 2019

Clinical case: Management of long-term antithrombotic therapy

Presenter: Giuseppe Tarantini

February 15, 2019

Presentation JIM 2019

Log-linear association per unit change in LDL-C and the risk of CV disease-a statin tale

Presenter: Bernardo Cortese

February 15, 2019

Presentation JIM 2019

Cangrelor is ready for the prime time

Presenter: Giuseppe Musumeci

February 15, 2019

Presentation JIM 2019

GP IIb/IIIa inhibitors are still the best option

Presenter: Alberto Menozzi

February 15, 2019

Presentation ISC 2019

Treatment of Factor Xa Inhibitor-Associated Bleeding with Andexanet Alfa: Full Results of ANNEXA-4

Presenter: Stuart J. Connolly

February 08, 2019

Advertisement

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

High-Dose Nifedipine Tied to Higher Cardiac Arrest Risk

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Optimal Duration of Antiplatelet Therapy – Does IV Imaging Make A Difference?

When treating (severely) calcified CAD, rotational or orbital atherectomy is mandatory

Show Me the Data: Evidence That Physiologic Lesion Assessment Improves Patient Outcomes

High Definition IVUS as a tool to optimize PCI

Basics of Coronary Physiology: FFR-Guided PCI in Stable CAD

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Majority of SCAD Lesions Heal With Conservative Treatment

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

CT Angiography Bests Functional Testing in Diabetic Patients With Chest Pain: PROMISE

Quality of CAD Care Varies by Type of Medicare Coverage

Consider Low Dose RIVAROXABAN + SAPT

Clinical case: Management of long-term antithrombotic therapy

Log-linear association per unit change in LDL-C and the risk of CV disease-a statin tale

Cangrelor is ready for the prime time

GP IIb/IIIa inhibitors are still the best option

Treatment of Factor Xa Inhibitor-Associated Bleeding with Andexanet Alfa: Full Results of ANNEXA-4

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content